Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brand/Generic Settlements Return To Capitol Hill

This article was originally published in The Pink Sheet Daily

Executive Summary

Apotex could make its case for scrapping first-to-file exclusivity during a hearing in Rep. Rush’s subcommittee.

You may also be interested in...



Brand/Generic Settlement Bill May Need Help From Authorized Generics Limits

Supporters of legislation to curb settlements between brand and generic firms may consider modifying their proposal to include limits on authorized generics to garner more support

Brand/Generic Settlement Bill May Need Help From Authorized Generics Limits

Supporters of legislation to curb settlements between brand and generic firms may consider modifying their proposal to include limits on authorized generics to garner more support

FTC Chairman To Be Jon Leibowitz: Will Reverse Payments Get More Scrutiny?

Jon Leibowitz, a fierce opponent of reverse settlements between brand name and generic companies, is set to head the Federal Trade Commission

Related Content

Topics

UsernamePublicRestriction

Register

PS069180

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel